Cirrhosis/Liver Failure News

WASHINGTON — Patients with cirrhosis in low- or middle-income countries had an increased risk for inpatient and 30-day mortality, likely due to disparities in transplant access, according to research presented at The Liver Meeting.

WASHINGTON — Patients with cirrhosis who received three doses of the COVID-19 mRNA vaccine, demonstrated an 80% reduced risk for SARS-COV-2 infection, symptomatic COVID-19, and moderate/severe/critical COVID-19, noted a presenter here.

WASHINGTON — Patient survival was no different for living donor liver transplant recipients with a MELD score greater than 25 compared with those with lower MELD scores, according to data presented at The Liver Meeting.

WASHINGTON — Age-standardized mortality rates for alcohol-associated liver disease and nonalcoholic fatty liver disease increased the most among the young and non-Hispanic whites, Blacks and Native Americans during the COVID-19 pandemic.

WASHINGTON — The Multi-Organ Dysfunction and Evaluation for Liver transplantation, or MODEL, score predicted high probability of mortality in transplant patients with severe acute-on-chronic liver failure, according to research.

WASHINGTON — The number of cases of alcohol-related hepatitis increased by more than 60% from 2019 to 2021 in three California hospitals, with women and young adults most affected, according to research presented at The Liver Meeting.

CHARLOTTE, N.C. — Local injury, toxin exposure and systemic disease were among the top contributors to development of diabetes mellitus in patients with acute pancreatitis, according to a researcher at the ACG Annual Scientific Meeting.

CHARLOTTE, N.C. — The CHESS-ALARM score was a better predictor of esophageal varices requiring treatment in patients with cirrhosis vs. other noninvasive criteria, according to data presented at the ACG Annual Scientific Meeting.

Patients with hepatorenal syndrome type 1 and advanced acute-on-chronic liver failure had significantly greater incidence of respiratory failure and 90-day mortality when treated with terlipressin vs. placebo, according to research.

Obeticholic acid failed to demonstrate superiority to placebo for improving fibrosis in patients with compensated cirrhosis due to nonalcoholic steatohepatitis in a phase 3 trial, according to an Intercept Pharmaceuticals press release.